Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Opioid Craving in Human Laboratory Settings: a Review of the Challenges and Limitations

  • 41 Accesses

  • 1 Citations

Abstract

There are many factors that need to be taken into consideration when measuring craving in a human laboratory study. This review summarizes and discusses some of the major challenges researchers are faced with when assessing opioid craving in clinical research. First, there are wide range of available assessments that have been developed for measuring craving and depending on the research questions or the underlying constructs targeted, some may be more appropriate than others. In addition to establishing the methodological point of departure for designing a study with craving, there are also different participant conditions and characteristics that need to be evaluated when selecting among the large selection of assessments available. Participant conditions/characteristics can influence the degree or frequency of opioid craving experienced. Lastly, there can be contextual conditions that affect opioid cravings such as a stressful environment that may alter cue saliency. It is recommended that researchers carefully consider the different constituents that contribute to opioid craving and to ensure a comprehensive evaluation when assessing each participant. A more thorough consideration of these challenges can help us to understand the optimal ways to measure one important and complex component of addiction.

This is a preview of subscription content, log in to check access.

References

  1. 1.

    Agrawal A, Wetherill L, Bucholz KK, et al. Genetic influences on craving for alcohol. Addict Behav. 2013;38(2):1501–8. https://doi.org/10.1016/j.addbeh.2012.03.021.

  2. 2.

    Anton RF, O'Malley SS, Ciraulo DA, et al. Combined pharmacotherapies and behavioral interventions for alcohol dependence: the COMBINE study: a randomized controlled trial. Jama. 2006;295(17):2003–17. https://doi.org/10.1001/jama.295.17.2003.

  3. 3.

    Back SE, Payne RL, Wahlquist AH, et al. Comparative profiles of men and women with opioid dependence: results from a national multisite effectiveness trial. Am J Drug Alcohol Abuse. 2011;37(5):313–23. https://doi.org/10.3109/00952990.2011.596982.

  4. 4.

    Back SE, Gros DF, Price M, et al. Laboratory-induced stress and craving among individuals with prescription opioid dependence. Drug Alcohol Depend. 2015;155:60–7. https://doi.org/10.1016/j.drugalcdep.2015.08.019.

  5. 5.

    Bordnick PS, Traylor A, Copp HL, et al. Assessing reactivity to virtual reality alcohol based cues. Addict Behav. 2008;33(6):743–56. https://doi.org/10.1016/j.addbeh.2007.12.010.

  6. 6.

    Connery HS. Medication-assisted treatment of opioid use disorder: review of the evidence and future directions. Harvard Rev Psychiatry. 2015;23(2):63–75. https://doi.org/10.1097/hrp.0000000000000075.

  7. 7.

    First MB. Structured Clinical Interview for the DSM (SCID). In The Encyclopedia of Clinical Psychology: Wiley. 2014.

  8. 8.

    Franken IHA, Hendriks VM, van den Brink W. Initial validation of two opiate craving questionnaires: The Obsessive Compulsive Drug Use Scale and the Desires for Drug Questionnaire. Addict Behav. 2002;27(5):675–85. https://doi.org/10.1016/S0306-4603(01)00201-5.

  9. 9.

    Goodyear K. Multisensory Environments to Measure Craving During Functional Magnetic Resonance Imaging. Alcohol and Alcoholism. 2019;54(3), 193–195.

  10. 10.

    Grace AA. The tonic/phasic model of dopamine system regulation and its implications for understanding alcohol and psychostimulant craving. Addiction. 2000;95(Suppl 2):S119–28.

  11. 11.

    Greenwald MK, Lundahl LH, Steinmiller CL. Yohimbine increases opioid-seeking behavior in heroin-dependent, buprenorphine-maintained individuals. Psychopharmacology (Berl). 2013;225(4):811–24. https://doi.org/10.1007/s00213-012-2868-9.

  12. 12.

    Haass-Koffler CL, Kenna GA. Bacchus by Caravaggio as the Visual Diagnosis of Alcohol Use Disorder from the Fifth Edition of the Diagnostic and Statistical Manual of Mental Disorders (DSM-5). Front Psychiatry. 2013;4:86. https://doi.org/10.3389/fpsyt.2013.00086.

  13. 13.

    Haass-Koffler CL, Leggio L, Kenna GA. Pharmacological Approaches to Reducing Craving in Patients with Alcohol Use Disorders. CNS Drugs. 2014;28(4):343–60. https://doi.org/10.1007/s40263-014-0149-3.

  14. 14.

    Haass-Koffler CL, Goodyear K, Zywiak WH, Leggio L, Kenna GA, Swift RM. Comparing and Combining Topiramate and Aripiprazole on Alcohol-Related Outcomes in a Human Laboratory Study. Alcohol Alcohol. 2018;53(3):268–76. https://doi.org/10.1093/alcalc/agx108.

  15. 15.

    Hyman SM, Fox H, Hong K-IA, Doebrick C, Sinha R. Stress and drug-cue-induced craving in opioid-dependent individuals in naltrexone treatment. Exp Clin Psychopharmacol. 2007;15(2):134–43. https://doi.org/10.1037/1064-1297.15.2.134.

  16. 16.

    Kirschbaum C, Pirke K-M, Hellhammer DH. The ‘Trier Social Stress Test’–a tool for investigating psychobiological stress responses in a laboratory setting. Neuropsychobiology. 1993;28(1-2):76–81.

  17. 17.

    Lankenau SE, Teti M, Silva K, Bloom JJ, Harocopos A, Treese M. Initiation into prescription opioid misuse amongst young injection drug users. Int J Drug Policy. 2012;23(1):37–44. https://doi.org/10.1016/j.drugpo.2011.05.014.

  18. 18.

    Larsen H, Engels RCME, Granic I, Overbeek G. An experimental study on imitation of alcohol consumption in same-sex dyads. Alcohol and Alcoholism. 2009;44(3):250–5. https://doi.org/10.1093/alcalc/agp002.

  19. 19.

    Leggio L, Zywiak WH, Edwards SM, Tidey JW, Swift RM, Kenna GA. A preliminary double-blind, placebo-controlled randomized study of baclofen effects in alcoholic smokers. Psychopharmacology. 2015;232(1):233–43. https://doi.org/10.1007/s00213-014-3652-9.

  20. 20.

    Ling W, Wesson DR. Clinical efficacy of buprenorphine: comparisons to methadone and placebo. Drug Alcohol Depend. 2003;70(2, Supplement):S49–57. https://doi.org/10.1016/S0376-8716(03)00059-0.

  21. 21.

    McHugh RK, Fulciniti F, Mashhoon Y, Weiss RD. Cue-induced craving to paraphernalia and drug images in opioid dependence. Am J Addict. 2016;25(2):105–9. https://doi.org/10.1111/ajad.12344.

  22. 22.

    Ray LA, Bujarski S, Yardley MM, Roche DJO, Hartwell EE. Differences between treatment-seeking and non-treatment-seeking participants in medication studies for alcoholism: do they matter? Am J Drug Alcohol Abuse. 2017;43(6):703–10. https://doi.org/10.1080/00952990.2017.1312423.

  23. 23.

    Ren Z-Y, Shi J, Epstein DH, Wang J, Lu L. Abnormal pain response in pain-sensitive opiate addicts after prolonged abstinence predicts increased drug craving. Psychopharmacology. 2009;204(3):423–9. https://doi.org/10.1007/s00213-009-1472-0.

  24. 24.

    Rosenblum A, Marsch LA, Joseph H, Portenoy RK. Opioids and the treatment of chronic pain: controversies, current status, and future directions. Exp Clin Psychopharmacol. 2008;16(5):405–16. https://doi.org/10.1037/a0013628.

  25. 25.

    Sayette MA, Shiffman S, Tiffany ST, Niaura RS, Martin CS, Schadel WG. The measurement of drug craving. Addiction. 2000;95(8s2):189–210.

  26. 26.

    Schuchat A, Houry D, Guy GP Jr. New Data on Opioid Use and Prescribing in the United StatesNew Data on Opioid Use and Prescribing, 2006-2015New Data on Opioid Use and Prescribing, 2006-2015. Jama. 2017;318(5):425–6. https://doi.org/10.1001/jama.2017.8913.

  27. 27.

    Shiffman S. Comments on craving. Addiction. 2000;95(8s2):171–5.

  28. 28.

    Tiffany ST, Wray JM. The clinical significance of drug craving. Ann N Y Acad Sci. 2012;1248(1):1–17.

  29. 29.

    Tiffany ST, Singleton E, Haertzen CA, Henningfield JE. The Development of a Heroin Craving Questionnaire. In: [unpublished manuscript] Purdue University. 1993.

  30. 30.

    Tiffany ST, Carter BL, Singleton EG. Challenges in the manipulation, assessment and interpretation of craving relevant variables. Addiction. 2000;95(Suppl 2):S177–87.

  31. 31.

    Weiss RD, Griffin ML, Hufford C. Craving in hospitalized cocaine abusers as a predictor of outcome. Am J Drug Alcohol Abuse. 1995;21(3):289–301.

Download references

Acknowledgments

Dr. Goodyear is supported by the National Institute on Alcohol Abuse and Alcoholism (K01 AA026874) and previously by the 5T32AA007459 training grant. Dr. Haass-Koffler is supported by the National Institute on Alcohol Abuse and Alcoholism (K01 AA023867; R01 AA026589; R01 AA027760) and by the National Institute of General Medical Sciences (NIGMS), Center of Biomedical Research Excellence (COBRE, P20 GM130414).

Required Author Forms

Disclosure forms provided by the authors are available with the online version of this article.

Author information

Correspondence to Kimberly Goodyear.

Ethics declarations

Conflict of Interest

The authors declare that they have no conflict of interest.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Electronic supplementary material

ESM 1

(PDF 498 kb)

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Goodyear, K., Haass-Koffler, C.L. Opioid Craving in Human Laboratory Settings: a Review of the Challenges and Limitations. Neurotherapeutics 17, 100–104 (2020). https://doi.org/10.1007/s13311-019-00791-8

Download citation

Key·Words

  • measurement
  • craving
  • human laboratory
  • assessments
  • opioids